You have free access to this content

Cancer

Cover image for Vol. 119 Issue 3

1 February 2013

Volume 119, Issue 3

Pages 471–700

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Erratum
    1. You have free access to this content
      Trial and error (pages 471–472)

      Carrie Printz

      Version of Record online: 22 JAN 2013 | DOI: 10.1002/cncr.27960

      • original image
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Erratum
    1. You have free access to this content
      Ovarian cancer : Making its own rules—again (pages 474–476)

      Elise C. Kohn and Jean Hurteau

      Version of Record online: 11 DEC 2012 | DOI: 10.1002/cncr.27833

      • original image
      • original image

      The field of ovarian cancer research has made marked progress in better understanding ovarian cancer and redefining its types. New information is putting into doubt that mutations in KRAS and/or BRAF always portend poor outcome, at least not in low-grade serous ovarian cancers.

    2. You have free access to this content
      Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma? (pages 477–480)

      Kevin B. Kim

      Version of Record online: 22 AUG 2012 | DOI: 10.1002/cncr.27756

      Bevacizumab and other drugs targeting vascular endothelial growth factor and/or its receptor have shown encouraging clinical outcomes in early-phase studies when they are combined with cytotoxic chemotherapy drugs. The success of bevacizumab or other antiangiogenic drugs in the treatment of patients with advanced melanoma will depend on a better understanding of tumoral neovascularization and its effect on tumor stromal tissues, as well as on selecting patients with appropriate relevant biomarkers to yield improved clinical outcomes.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Determining the impact of US mammography screening guidelines on patient survival in a predominantly African American population treated in a public hospital during 2008 (pages 481–487)

      Imnett Habtes, Danielle Friedman, Cheryl Raskind-Hood, Kathleen Adams, Edmund R. Becker, Carl D'Orsi, George Birdsong, Kathleen Gundry, Ruth O'Regan and Sheryl G. A. Gabram

      Version of Record online: 1 AUG 2012 | DOI: 10.1002/cncr.27698

      The modeled implementation of later and less frequent mammography screening as a potential impact of the revised 2009 US Preventive Service Task Force guidelines may cause women to be diagnosed at later stages of breast cancer. Public hospitals that serve predominantly African American women appear to be disproportionately negatively impacted by the guideline revision, because this population tends to develop earlier and more aggressive breast cancer; thus, health care providers should prioritize discussions regarding the benefits and risks of annual mammographic screening, especially among women who have a potentially greater risk of developing breast cancer at a younger age.

    2. You have free access to this content
      Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women (pages 488–494)

      Theresa Schwartz, Azadeh Stark, Judy Pang, Baffour Awuah, Celina G. Kleer, Solomon Quayson, Stephanie Kingman, Francis Aitpillah, Francis Abantanga, Evelyn Jiagge, Joseph K. Oppong, Ernest Osei-Bonsu, Iman Martin, Xiaowei Yan, Kathy Toy, Ernest Adjei, Max Wicha and Lisa A. Newman

      Version of Record online: 28 AUG 2012 | DOI: 10.1002/cncr.27737

      Mammary stem cells, as identified by cells expressing the marker aldehyde dehydrogenase 1 (ALDH1), appear to be correlated with malignant transformation and progression of breast tissue into biologically aggressive phenotypes. This study reveals increased expression of ALDH1 in benign and malignant tissue of women from the western sub-Saharan African nation of Ghana, a population known to have higher frequency of triple-negative breast cancer, and ALDH1 expression in the malignant specimens was found to be associated with risk of triple-negative breast cancer.

    3. You have free access to this content
      Added cancer yield of breast magnetic resonance imaging screening in women with a prior history of chest radiation therapy (pages 495–503)

      Vivianne Freitas, Anabel Scaranelo, Ravi Menezes, Supriya Kulkarni, David Hodgson and Pavel Crystal

      Version of Record online: 5 SEP 2012 | DOI: 10.1002/cncr.27771

      • original image
      • original image

      Magnetic resonance imaging (MRI) is a useful adjunct modality to screen high-risk women with a previous history of chest radiation therapy, resulting in a 4.1% (4 of 98 women) added cancer detection rate. The results of this study support American Cancer Society recommendations that advise annual breast MRI screening in patients with a prior history of chest radiation therapy.

    4. Endocrine Disease
      You have free access to this content
      Hurthle cell carcinoma : A population-level analysis of 3311 patients (pages 504–511)

      Paolo Goffredo, Sanziana A. Roman and Julie A. Sosa

      Version of Record online: 14 AUG 2012 | DOI: 10.1002/cncr.27770

      • original image
      • original image

      Hurthle cell carcinoma has a more aggressive behavior and a shorter survival than other differentiated thyroid cancers. The authors suggest that Hurthle cell carcinoma should be considered a unique disease entity, and more targeted guidelines could be proposed.

    5. Gastrointestinal Disease
      You have free access to this content
      Dietary patterns and colorectal adenomas in Lynch syndrome : The GEOLynch cohort study (pages 512–521)

      Akke Botma, Hans F. A. Vasen, Fränzel J. B. van Duijnhoven, Jan H. Kleibeuker, Fokko M. Nagengast and Ellen Kampman

      Version of Record online: 17 DEC 2012 | DOI: 10.1002/cncr.27726

      Dietary habits may influence risk of colorectal adenomas among patients with Lynch syndrome. This study among 486 individuals with Lynch syndrome showed a doubling of adenoma risk (hazard ratio, 2.16; 95% confidence interval, 1.03-4.49) for those who score high on a “Snack” pattern as compared to those scoring low on this dietary pattern.

      Corrected by:

      Errata: Errata: Dietary patterns and colorectal adenomas in Lynch syndrome

      Vol. 119, Issue 12, 2358, Version of Record online: 19 MAR 2013

    6. You have free access to this content
      PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma (pages 522–528)

      David V. Gold, Jochen Gaedcke, B. Michael Ghadimi, Michael Goggins, Ralph H. Hruban, Mengling Liu, Guy Newsome and David M. Goldenberg

      Version of Record online: 16 AUG 2012 | DOI: 10.1002/cncr.27762

      • original image
      • original image
      • original image

      The monoclonal antibody PAM4 has high specificity for pancreatic ductal adenocarcinoma (PDAC), as well as its precursor lesions, but has not been found to be reactive with normal and benign pancreatic tissues. In the current study, the authors report that a combined PAM4 and carbohydrate antigen (CA) 19-9 biomarker serum assay can provide high sensitivity for the detection of early stage PDAC with high diagnostic accuracy.

    7. You have free access to this content
      HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma (pages 529–539)

      Anne Nguyen Kovochich, Michael Arensman, Anna R. Lay, Nagesh P. Rao, Timothy Donahue, Xinmin Li, Samuel W. French and David W. Dawson

      Version of Record online: 22 AUG 2012 | DOI: 10.1002/cncr.27725

      • original image
      • original image
      • original image
      • original image

      The homeobox B7 (HOXB7) gene is frequently overexpressed in pancreatic adenocarcinoma, in which it promotes an invasive phenotype and is associated with lymph node metastasis and poor survival. HOXB7 or its downstream targets represent potential clinical biomarkers or therapeutic targets in those cancers in which it is deregulated.

    8. Genitourinary Disease
      You have free access to this content
      A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer : Final results (pages 540–547)

      Arlene O. Siefker-Radtke, Colin P. Dinney, Yu Shen, Dallas L. Williams, Ashish M. Kamat, H. Barton Grossman and Randall E. Millikan

      Version of Record online: 22 AUG 2012 | DOI: 10.1002/cncr.27751

      • original image
      • original image
      • original image

      Neoadjuvant chemotherapy improves the survival of patients with high-risk urothelial cancer. Sequential chemotherapy is quite active and at least maintains the historic expectation of achieving a cure. The current results strongly reinforce previous experience and suggest that pathologic downstaging to pathologic T1 disease or lower is a useful surrogate for an eventual cure.

    9. Gynecologic Oncology
      You have free access to this content
      BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer (pages 548–554)

      Rachel N. Grisham, Gopa Iyer, Karuna Garg, Deborah DeLair, David M. Hyman, Qin Zhou, Alexia Iasonos, Michael F. Berger, Fanny Dao, David R. Spriggs, Douglas A. Levine, Carol Aghajanian and David B. Solit

      Version of Record online: 28 AUG 2012 | DOI: 10.1002/cncr.27782

      • original image
      • original image
      • original image
      • original image

      The valine-to-glutamate substitution at residue 600 (V600E) in BRAF mutation is present in 35% of serous borderline/low-grade serous ovarian cancers, and presence of the BRAF V600E mutation in these cancers is associated with early stage disease and an improved prognosis. Patients with serous borderline/low-grade serous cancers who require systemic therapy are unlikely to have tumors with BRAF mutations.

    10. You have free access to this content
      Metformin intake is associated with better survival in ovarian cancer : A case-control study (pages 555–562)

      Sanjeev Kumar, Alexandra Meuter, Prabin Thapa, Carrie Langstraat, Shailendra Giri, Jeremy Chien, Ramandeep Rattan, William Cliby and Viji Shridhar

      Version of Record online: 3 DEC 2012 | DOI: 10.1002/cncr.27706

      • original image
      • original image
      • original image
      • original image
      • original image

      Metformin intake is associated with better survival in women with ovarian cancer. The current analyses indicate that metformin should be tested in prospective clinical trials in ovarian cancer.

    11. Head and Neck Disease
      You have free access to this content
      Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1α,25-dihydroxycholecalciferol (pages 563–574)

      Yingyu Ma, Wei-Dong Yu, Bing Su, Mukund Seshadri, Wei Luo, Donald L. Trump and Candace S. Johnson

      Version of Record online: 25 JUL 2012 | DOI: 10.1002/cncr.27531

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The active vitamin D metabolite 1α,25-dihydroxycholecalciferol (1,25D3) inhibits squamous cell carcinoma (SCC) cell migration and invasion in vitro and suppresses SCC lung metastasis in vivo. In addition, 1,25D3 promotes the expression of E-cadherin, which contributes to its inhibition of SCC cell motility.

    12. Hepatobiliary Disease
      You have free access to this content
      Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer (pages 575–585)

      Dipok Kumar Dhar, Steven W.M. Olde Damink, James Hal Brindley, Andrew Godfrey, Michael H. Chapman, Neomal S. Sandanayake, Fausto Andreola, Sybille Mazurek, Tayyaba Hasan, Massimo Malago and Stephen P. Pereira

      Version of Record online: 1 AUG 2012 | DOI: 10.1002/cncr.27611

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      This is the first study of its kind showing that the level of pyruvate kinase M2 in bile is a diagnostic marker for biliary tract cancer, with 90% sensitivity and 84% specificity. Genetic manipulation of pyruvate kinase M2 expression in biliary tract cancer cell lines demonstrated its association with an aggressive cancer phenotype of rapid growth, invasion, and angiogenesis.

    13. Melanoma
      You have free access to this content
      A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : A North Central Cancer Treatment Group study, N0775 (pages 586–592)

      Lisa A. Kottschade, Vera J. Suman, Domingo G. Perez, Robert R. McWilliams, Judith S. Kaur, Thomas T. Amatruda III, Francois J. Geoffroy, Howard M. Gross, Peter A. Cohen, Anthony J. Jaslowski, Matthew L. Kosel and Svetomir N. Markovic

      Version of Record online: 22 AUG 2012 | DOI: 10.1002/cncr.27760

      • original image
      • original image
      • original image

      Metastatic melanoma continues to remain a devastating disease with few treatment options. This study indicates that the addition of bevacizumab to the combination of nab-paclitaxel and carboplatin shows initially promising activity worthy of further investigation.

    14. Discipline

      Clinical Trials
      You have free access to this content
      Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials (pages 593–601)

      Paul F. Pinsky, Amanda Black, Robert Grubb, E. David Crawford, Gerald Andriole, Ian Thompson and Howard Parnes

      Version of Record online: 14 AUG 2012 | DOI: 10.1002/cncr.27774

      The Prostate Cancer Prevention Trial (PCPT) and Reduction by Dutasteride of Prostate Cancer Events (REDUCE) chemoprevention trials demonstrated substantial overall reductions in prostate cancer incidence but hints of an increased rate of high-grade disease. A projection of the mortality outcomes of these trials suggests a possibly modest mortality benefit for these agents and, at worst, a small mortality excess.

    15. You have free access to this content
      Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation : Prospective clinical and socioeconomic evaluation (pages 602–611)

      Didier Blaise, Reza Tabrizi, Jean-Marie Boher, Anne-Gaëlle Le Corroller-Soriano, Jacques-Olivier Bay, Nathalie Fegueux, Jean-Michel Boiron, Sabine Fürst, Luca Castagna, Christian Chabannon, Agnes Boyer-Chammard, Noël Milpied, Hélène Labussière-Wallet, Catherine Faucher, Valerie-Jeanne Bardou, Mohamad Mohty and Mauricette Michallet

      Version of Record online: 14 AUG 2012 | DOI: 10.1002/cncr.27786

      • original image
      • original image
      • original image
      • original image
      • original image

      The authors present the results from a randomized phase 2 study comparing 2 reduced-intensity conditioning strategies with different intensity levels. The more intensive strategy is associated with better disease control but higher nonrelapse mortality.

    16. Disparities Research
      You have free access to this content
      Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities (pages 612–620)

      Lina Jandorf, Lauren M. Stossel, Julia L. Cooperman, Joshua Graff Zivin, Uri Ladabaum, Diana Hall, Linda D. Thélémaque, William Redd and Steven H. Itzkowitz

      Version of Record online: 25 JUL 2012 | DOI: 10.1002/cncr.27759

      • original image

      Patient navigation increases screening colonoscopy completion rates among a diverse urban patient population of under-represented minorities. Patient navigation leads to increased colonoscopy completion rates as well as additional net income to the institution in patients with mostly public health insurance.

    17. You have free access to this content
      Provider factors associated with disparities in human papillomavirus vaccination among low-income 9- to 17-year-old girls (pages 621–628)

      Susan T. Vadaparampil, Stephanie A. S. Staras, Teri L. Malo, Katie Z. Eddleton, Juliette Christie, Maria Rodriguez, Anna R. Giuliano and Elizabeth A. Shenkman

      Version of Record online: 1 AUG 2012 | DOI: 10.1002/cncr.27735

      Human papillomavirus (HPV) vaccination rates were higher among providers who: were pediatricians, had a private practice, practiced in a single specialty setting, were providers under the Vaccines for Children program, saw primarily non-Hispanic white patients, used 2 or more strategies for vaccine series completion, and did not refer out for HPV vaccination. Study findings can be used to target health services interventions to providers least likely to administer HPV vaccine to female Medicaid enrollees.

    18. Epidemiology
      You have free access to this content
      Survival of patients with marginal zone lymphoma : Analysis of the Surveillance, Epidemiology, and End Results database (pages 629–638)

      Adam J. Olszewski and Jorge J. Castillo

      Version of Record online: 14 AUG 2012 | DOI: 10.1002/cncr.27773

      • original image
      • original image
      • original image
      • original image

      The prognosis of mucosa-associated lymphoid tissue (MALT) lymphoma is better than that of the splenic or nodal subtypes. Although survival in patients with MALT and nodal marginal zone lymphomas has improved over the past decade, the prognosis of patients with MALT lymphomas depends on the anatomical site of origin.

    19. Outcomes Research
      You have free access to this content
      Surgical treatment of colon cancer in patients aged 80 years and older : Analysis of 31,574 patients in the SEER-Medicare database (pages 639–647)

      Heather B. Neuman, Erin S. O'Connor, Jennifer Weiss, Noelle K. LoConte, David Y. Greenblatt, Caprice C. Greenberg and Maureen A. Smith

      Version of Record online: 14 AUG 2012 | DOI: 10.1002/cncr.27765

      • original image
      • original image
      • original image

      The objective of the current study was to examine outcomes in patients aged ≥ 80 years with colon cancer who were treated with and without colectomy. Approximately 80% of patients underwent colectomy; survival was found to be decreased for the 46% who underwent urgent/emergent surgery. For both operative and nonoperative patients, the 1-year overall survival rate was lower than the colon cancer-specific survival rate (operative patients: 78% vs 89%; nonoperative patients: 58% vs 78%).

    20. You have free access to this content
      Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States (pages 648–655)

      Alok A. Khorana, Mehul Dalal, Jay Lin and Gregory C. Connolly

      Version of Record online: 14 AUG 2012 | DOI: 10.1002/cncr.27772

      • original image
      • original image
      • original image
      • original image
      • original image

      This real-world, contemporary cohort study examines the incidence and predictors of venous thromboembolism in ambulatory patients initiating chemotherapy for select solid tumors. Targeting high-risk cancer outpatients with appropriate prophylaxis may reduce the clinical burden of venous thromboembolism and its consequences.

    21. Pediatric Oncology
      You have free access to this content
      The degree of tumor volume reduction during the early phase of induction chemotherapy is an independent prognostic factor in patients with high-risk neuroblastoma (pages 656–664)

      So Young Yoo, Jung-Sun Kim, Ki Woong Sung, Tae Yeon Jeon, Joon Young Choi, Seung Hwan Moon, Meong Hi Son, Soo Hyun Lee, Keon Hee Yoo and Hong Hoe Koo

      Version of Record online: 5 SEP 2012 | DOI: 10.1002/cncr.27775

      • original image
      • original image
      • original image
      • original image

      A greater reduction in tumor volume during the early phase of induction chemotherapy is associated with a better outcome in patients with high-risk neuroblastoma. Tailoring treatment intensity according to the early tumor response to induction chemotherapy may improve patient outcomes.

    22. You have free access to this content
      Ifosfamide, carboplatin, and etoposide for neuroblastoma : A high-dose salvage regimen and review of the literature (pages 665–671)

      Brian H. Kushner, Shakeel Modak, Kim Kramer, Ellen M. Basu, Stephen S. Roberts and Nai-Kong V. Cheung

      Version of Record online: 5 SEP 2012 | DOI: 10.1002/cncr.27783

      Antineuroblastoma activity and tolerable toxicity are evident both in a large experience with a high-dose ifosfamide, carboplatin, and etoposide regimen in 74 patients with resistant disease and in a literature review. The findings support the use of this triple-drug combination in patients with neuroblastoma.

    23. Quality of Life
      You have free access to this content
      Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma (pages 672–680)

      Roxanne E. Jensen, Neeraj K. Arora, Keith M. Bellizzi, Julia H. Rowland, Ann S. Hamilton, Noreen M. Aziz and Arnold L. Potosky

      Version of Record online: 5 SEP 2012 | DOI: 10.1002/cncr.27781

      • original image
      • original image
      • original image

      This community-based sample of survivors of aggressive non-Hodgkin lymphoma 2 to 5 years after diagnosis demonstrates that survivors who are younger, not married, lack private insurance, or experience a greater illness burden may be at risk for experiencing poorer health-related quality of life. Cognitive health appraisal factors are strongly related to health-related quality of life, suggesting the potential benefits of interventions focused on these mutable factors for this population.

    24. Radiation Oncology
      You have free access to this content
      The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer (pages 681–690)

      Mark Shilkrut, Gregory S. Merrick, P. William McLaughlin, Matthew H. Stenmark, Eyad Abu-Isa, Sean M. Vance, Howard M. Sandler, Felix Y. Feng and Daniel A. Hamstra

      Version of Record online: 14 AUG 2012 | DOI: 10.1002/cncr.27784

      • original image
      • original image
      • original image

      The authors retrospectively analyze the impact of combined-modality radiation therapy on clinical outcomes in 958 patients with high-risk prostate cancer. The addition of an interstitial brachytherapy boost and long-term androgen suppression significantly decreases the rates of biochemical failure and prostate cancer death compared with dose-escalated radiotherapy.

    25. Symptom Control and Palliative Care
      You have free access to this content
      Predictors of newly diagnosed cancer patients' understanding of the goals of their care at initiation of chemotherapy (pages 691–699)

      Inga T. Lennes, Jennifer S. Temel, Christen Hoedt, Ashley Meilleur and Elizabeth B. Lamont

      Version of Record online: 25 SEP 2012 | DOI: 10.1002/cncr.27787

      • original image
      • original image

      The authors surveyed patients with newly diagnosed solid tumors who were receiving chemotherapy for the first time and observed that a substantial number of patients misunderstood the objective of their chemotherapy treatment. The most common misunderstanding was that patients believed they were being treated for cure rather than palliation.

  4. Erratum

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Erratum
    1. You have free access to this content
      Erratum (page 700)

      Version of Record online: 14 AUG 2012 | DOI: 10.1002/cncr.27747

      This article corrects:

      Preoperative chemotherapy for bladder cancer1

      Vol. 118, Issue 1, 8–11, Version of Record online: 5 JUL 2011

SEARCH

SEARCH BY CITATION